Perrigo Company plc Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Perrigo Company plc (PRGO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-26
- Perrigo Company plc share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $0.00.
- Perrigo Company plc share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $0.00.
- Perrigo Company plc share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $0.00.
- Perrigo Company plc share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $0.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | |
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | |
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 | |
| 2022-12-31 | $0.00 10-K · filed 2025-02-28 | |
| 2021-12-31 | $0.00 10-K · filed 2024-02-27 | |
| 2020-12-31 | $0.00 10-K · filed 2024-02-27 | |
| 2019-12-31 | $500.00K 10-K · filed 2022-03-01 | |
| 2018-12-31 | $1.10M 10-K · filed 2021-03-01 | |
| 2017-12-31 | $1.70M 10-K · filed 2020-02-27 | |
| 2016-12-31 | $5.20M 10-K · filed 2019-02-27 | |
| 2015-12-31 | $6.70M 10-K · filed 2018-03-01 | |
| 2015-06-27 | $20.70M 10-K · filed 2018-03-01 | |
| 2014-06-28 | $17.80M 10-K · filed 2017-05-22 | |
| 2013-06-29 | $29.50M 10-KT · filed 2016-02-25 | |
| 2012-06-30 | $38.90M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |